Nature of the business and basis of presentation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Clinicaltrial	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Organization, consolidation and presentation of financial statements [Line Items]
Additional Paid in Capital	$ 1,040,200
Proceeds from the sale of redeemable convertible preferred stock	90,500
Proceeds from its initial public offering	105,800
Proceeds from the sales of common stock in equity offerings	818,900
Venture debt borrowings	25,000
Proceeds from equity investment from Pfizer, Inc.	25,000
Net loss	151,759	$ 112,033	$ 100,777
Accumulated deficit	(574,096)	$ (422,337)
Cash, cash equivalents and short-term marketable securities	$ 569,293
SYMMETRY Study | NASH Patients with Compensated Cirrhosis
Organization, consolidation and presentation of financial statements [Line Items]
Number of planned clinical trials | Clinicaltrial	3